Medigene sells partial stake in Immunocore
(Thomson Reuters ONE) -
Medigene AG /
Medigene sells partial stake in Immunocore
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 04 April 2016. Medigene AG (MDG1, Frankfurt, Prime
Standard), a clinical stage immune-oncology company focussing on the development
of T cell-based immunotherapies for the treatment of cancer, announces that it
has today sold 50% of its' stake in the private biotech company Immunocore Ltd.,
UK, for approximately 4.9 million GBP (approx. ? 6.1 million).
Medigene held 64,815 ordinary shares in Immunocore which were valued at 2.8
million GBP (approx. ? 3.6 million) in 2014.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology
company headquartered in Martinsried near Munich, Germany. The company is
developing highly innovative, complementary treatment platforms to target
various types and stages of cancer with candidates in clinical and pre-clinical
development. Medigene concentrates on the development of personalised T-cell-
based immunotherapies.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) is a registered trademark of Medigene AG. This trademark may be
owned or licensed in select locations only.
Contact Medigene
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
In case you no longer wish to receive any information about Medigene, please
inform us by e-mail (investor(at)medigene.com). We will then delete your address
from our distribution list.
Press release English PDF:
http://hugin.info/132073/R/2000389/737954.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
[HUG#2000389]
Unternehmensinformation / Kurzprofil:
Datum: 04.04.2016 - 18:01 Uhr
Sprache: Deutsch
News-ID 461707
Anzahl Zeichen: 2740
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 237 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene sells partial stake in Immunocore"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
